Aor’s New Red Yeast Rice Formula Ryr Ankascin -568-R™ Offers the Cardiovascular Health Benefits of Statins but Without the Side Effects
Developed by AOR, RYR Ankascin -568-R™ is the Only Patented, Clinically Studied, Regulatory Compliant, and Commercially Available Red Yeast Rice Extract Free of Monacolin K.
1Red Yeast Rice (RYR) is a natural health product typically used as a secondary option for statins, which are a class of drug prescribed by physicians for cardiovascular conditions such as high cholesterol. Despite being a natural product, conventional RYR products on the market have caused controversy due to the presence of monacolin K.
Monacolin K is naturally occurring statin and one of the active compounds present in RYR, which produces similar side effects to lovastatin, which is found in the cholesterol-lowering prescription drugs such as Mevacor®. Some patients on prolonged or high doses of these statins can experience negative side effects including; myopathy, muscle symptoms including pain and weakness and rhabdomyolsis, a condition in which muscle fibers break down, releasing harmful substances into the bloodstream which can lead to liver and kidney damage. RYR Ankascin -568-R™ is a new product from Canadian company, Advanced Orthomolecular Research (AOR), which unlike any other product on the market is completely free of monacolin K.
RYR Ankascin -568-R™ is produced by fermenting rice with red yeast Monascus purpureus (a species of mold) and then subjecting it to a patented extraction process that removes the toxic bi-product citrinin. The new monacolin K-free RYR Ankascin -568-R™ product offers several exciting health benefits, which target multiple symptoms of metabolic syndrome without the negative side effects associated with statin drug usage. RYR Ankascin -568-R™ has successfully completed two human clinical trials for cholesterol reduction, one preliminary study for blood pressure and one study for blood sugar reduction. Further, a small human pilot study has been completed for reducing various biomarkers of Alzheimer’s disease and additional studies are underway.
Dr. Traj Nibber, founder and Director of Research at AOR, stated, “RYR Ankascin -568-R™ is the world’s first red yeast rice product that does not contain any monocolin K and the toxic citrinin bi-product. Monocolin K levels are highly regulated by Health Canada and the Food and Drug Association (FDA), and many RYR products on the market are non-compliant. AOR guarantees that its RYR Ankascin -568-R™ complies with all regulatory jurisdictions unlike other RYR products on the market.”
Due to the unique and novel bioactive substances in RYR Ankascin -568-R™ including ankaflavin and monascin, RYR Ankascin -568R™ works in multiple ways to help manage several conditions associated with metabolic syndrome. Dr. Nibber believes that “this product is ideally suited against metabolic syndrome that has become the scourge of health all over the world!” AOR’s monacolin K-free RYR fast release softgels have been formulated and manufactured by AOR to contain 110 mg of RYR, providing 3.3 mg of monascin and 1.14 mg of ankaflavin. The softgel format allows the product to be absorbed faster by the body equating to a fast acting and safer solution for people with metabolic syndrome concerns.
Consumers interested in monacolin K free RYR are likely aware of the toxicity issues of other RYR products currently on the market. AOR’s monacolin K free product offers a safer alternative to consumers in various countries where RYR is not available in a monacolin K free format. RYR Ankascin -568-R™ is filling the void for health conscious consumers across international markets.
AOR, a Canadian-based company with headquarters in Calgary, Canada, has an established reputation over the last 25 years as being one of the most advanced supplement formulators in the country. AOR endeavors to bring something new to the supplement world: not just new supplements, but a new spirit. AOR is built around the pillars of innovative research, scientific integrity, quality manufacturing, and consumer education. "Orthomolecule" was a term coined by Linus Pauling, who is the founder of orthomolecular medicine and a Nobel Prize winner in 1954 and Nobel Peace Prize winner in 1962. Orthomolecular refers to "the right amount of the right substances delivered to the right place in the body at the right time."
